D-1121-2019 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1121-2019 was initiated by Lupin Pharmaceuticals Inc. on Apr 1, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications; 18 month long term stability study. The recall status is terminated (terminated Jul 1, 2020). Affected quantity: 12,504 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 17, 2019
Initiation Date
Apr 1, 2019
Termination Date
Jul 1, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,504 bottles

Product description

Telmisartan and Amlodipine Tablets 80 mg/5 mg, 30 tablet bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by : Lupin Limited, Goa, INDIA -- NDC 68180-198-06

Reason for recall

Failed Impurities/Degradation Specifications; 18 month long term stability study.

Distribution pattern

Product was distributed to 6 wholesalers/ drug chains and 2 mail order pharmacies that may have further distribute the product throughout the United States.

Code information

G705843 Exp. date April, 2019 G707763 Exp. date August, 2019 G800434 Exp. date November, 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1121-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1121-2019. Report a data issue: hello@regdatalab.com.